RecruitingPhase IIEN originalColorectal cancerMetastatic / advanced

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Potwierdzony zaawansowany rak jelita grubego, który nie może być operacyjnie usunięty
  • Dobry ogólny stan zdrowia (ECOG 0-1)
  • Brak wcześniejszego leczenia systemowego (chemioterapii) zaawansowanego raka jelita grubego
  • Guz z dodatnią ekspresją PD-L1 (wynik z centralnego laboratorium)

✗ Disqualifies

  • Wysoka niestabilność mikrosatelitów (MSI-H) lub defekt naprawy błędów DNA (dMMR)
  • Mutacja BRAF V600E
  • Niemożność przełykania tabletek
  • Historia lub obecne schorzenie płuc (włóknienie, zapalenie, fibróza płucna)
  • Aktywna choroba autoimmunologiczna
  • Wcześniejsze leczenie immunoterapią checkpoint (anti-PD-1, anti-PD-L1, anti-CTLA-4)

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 16, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (39)

Mayo Clinic Arizona

Phoenix, United States

USC Norris Comprehensive Cancer Center

Los Angeles, United States

Rocky Mountain Cancer Centers, LLP

Lone Tree, United States

Mayo Clinic Florida

Jacksonville, United States

Advent Health

Orlando, United States

May Clinic Rochester

Rochester, United States

The Ohio State University Comprehensive Cancer Center

Columbus, United States

Thomas Jefferson University, Sidney Kimmel Cancer Center

Philadelphia, United States

Baylor Scott & White Medical Center

Temple, United States

Virginia Oncology Associates

Norfolk, United States

Blue Ridge Cancer Care

Salem, United States

The Ottawa Hospital Cancer Centre

Ottawa, Canada

Princess Margaret Cancer Centre- University Health Network

Toronto, Canada

Jewish General Hospital

Montreal, Canada

CHU Besançon - Hôpital Jean Minjoz

Besançon, France

CHU Bordeaux - Hôpital Haut-Lévêque

Pessac, France

Chru De Nantes Hotel-Dieu

Nantes, France

Hôpital de la Timone

Marseille, France

Hôpital Européen Georges Pompidou

Paris, France

Hôpital Saint-Antoine

Paris, France

Centre Leon Berard

Lyon, France

CHU Poitiers - Hôpital la Milétrie

Poitiers, France

Azienda Socio Sanitaria Territoriale Niguarda

Milan, Italy

Istituto Clinico Humanitas

Milan, Italy

Istituto Europeo di Oncologia

Milan, Italy

AOU Uni degli Studi Della Campania Lugi Vanvitelli

Naples, Italy

Istituto Nazionale Tumori Fondazione G. Pascale

Naples, Italy

IOV-Istituto Oncologico

Padova, Italy

Kobe City Medical Center General Hospital

Hyōgo, Japan

National Hospital Organization Osaka National Hospital

Osaka, Japan

Osaka General Medical Center

Osaka, Japan

Osaka International Cancer Institute

Osaka, Japan

Institut Catala d'Oncologia (H. Germans Trias I Pujol, ICO-Barcelona)

Badalona, Spain

Hosptial Universitari Vall d'Hebron

Barcelona, Spain

Hospital Universitario Reina Sofia

Córdoba, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Hospital Universitario Virgen del Rocio

Seville, Spain

Hospital Regional Universitario de Malaga

Málaga, Spain

Hospital General Universitario de Valencia

Valencia, Spain

Trial contact

North America Clinical Trial Support Desk

International Clinical Trial Support Desk

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.